Fate Therapeutics Company

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Last Funding Type: Post-IPO Equity
Funding Status: IPO
Headquarters: United States
Founded Date: 2007
Investor Type: N/A
Investment Stage: N/A
Total Funding: $360.2M
Technology: mHealth
Employee Number: 11-50
Number Of Exists: N/A
Estimated Revenue: $1M to $10M
Investors Number: 7
Industry: Genomic and Epigenominc Instabillity